© 2004 by Oxford University Press
© 2004 Oxford University Press
ARTICLE |
Intermediate End Point for Prostate Cancer–Specific Mortality Following Salvage Hormonal Therapy for Prostate-Specific Antigen Failure
Affiliations of authors: Department of Radiation Oncology (AVD, KC, ML) and Department of Pathology (AAR), Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, MA; Department of Surgery and Urology Service, Center for Prostate Disease Research, Uniformed Services University and Walter Reed Army Medical Center, Bethesda, MD (JWM, LS); Department of Urology, University of California, San Francisco (PRC, DL); Department of Statistics, University of Connecticut, Storrs (MHC).
Correspondence to: Anthony V. D'Amico, MD, PhD, Brigham and Women's Hospital, Department of Radiation Oncology, 75 Francis St., ASBI, L2, Boston, MA 02115 (e-mail: adamico{at}lroc.harvard.edu)
Background: Whether the prostate-specific antigen (PSA) response to salvage hormonal therapy can act as an intermediate end point for prostate cancer–specific mortality (PCSM) remains unclear. Therefore, we evaluated whether PSA response, defined as the absolute value of the ratio of the rate of PSA change after salvage hormonal therapy to the rate of PSA change before salvage therapy, is associated with the time to PCSM following salvage hormonal therapy. Methods: A single-institution and two pooled multi-institution databases containing baseline, treatment, and follow-up information on men who received salvage hormonal therapy for PSA failure following surgery or radiation therapy from January 1, 1988, to January 1, 2002, formed the study (n = 199) and validation cohorts (n = 1255), respectively. The ability of PSA response and its constituents (i.e., pre–salvage hormonal therapy PSA slope and post–salvage hormonal therapy PSA slope) to predict time to PCSM following salvage hormonal therapy was assessed using Cox regression analysis. For illustrative purposes, PSA response was analyzed as a dichotomous variable with a breakpoint for the ratio of PSA response of 1. All statistical tests were two-sided. Results: PSA response was statistically significantly associated with time to PCSM following salvage hormonal therapy in both the study (PCox = .0014) and validation (PCox<.001) cohorts; however, its constituents were not (pre–salvage hormonal therapy PSA slope: PCox-study = .97, PCox-validation = .57; post–salvage hormonal therapy PSA slope: PCox-study = .27, PCox-validation = .31). Patients with a PSA response that was less than or equal to 1 had a statistically significantly shorter time to PCSM than patients with a PSA response of greater than 1 in both the study (hazard ratio [HR] = 3.6, 95% confidence interval [CI] = 1.3 to 10.3; PCox = .01) and validation (HR = 12.8, 95% CI = 6.2 to 26.3; PCox<.001) cohorts. Conclusion: The PSA response to salvage hormonal therapy can serve as an intermediate end point for PCSM in patients with a rising PSA level following surgery or radiation therapy.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. J. Armstrong, E. Garrett-Mayer, Y.-C. Ou Yang, M. A. Carducci, I. Tannock, R. de Wit, and M. Eisenberger Prostate-Specific Antigen and Pain Surrogacy Analysis in Metastatic Hormone-Refractory Prostate Cancer J. Clin. Oncol., September 1, 2007; 25(25): 3965 - 3970. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Loblaw, K. S. Virgo, R. Nam, M. R. Somerfield, E. Ben-Josef, D. S. Mendelson, R. Middleton, S. A. Sharp, T. J. Smith, J. Talcott, et al. Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer: 2007 Update of an American Society of Clinical Oncology Practice Guideline J. Clin. Oncol., April 20, 2007; 25(12): 1596 - 1605. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. M. Thompson Jr, C. M. Tangen, J. Paradelo, M. S. Lucia, G. Miller, D. Troyer, E. Messing, J. Forman, J. Chin, G. Swanson, et al. Adjuvant Radiotherapy for Pathologically Advanced Prostate Cancer: A Randomized Clinical Trial. JAMA, November 15, 2006; 296(19): 2329 - 2335. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P Singh, A Uzgare, I Litvinov, S R Denmeade, and J T Isaacs Combinatorial androgen receptor targeted therapy for prostate cancer. Endocr. Relat. Cancer, September 1, 2006; 13(3): 653 - 666. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. F. Slovin, A. S. Wilton, G. Heller, and H. I. Scher Time to Detectable Metastatic Disease in Patients with Rising Prostate-Specific Antigen Values following Surgery or Radiation Therapy Clin. Cancer Res., December 15, 2005; 11(24): 8669 - 8673. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. I. Scher, M. J. Morris, W. K. Kelly, L. H. Schwartz, and G. Heller Prostate Cancer Clinical Trial End Points: "RECIST"ing a Step Backwards Clin. Cancer Res., July 15, 2005; 11(14): 5223 - 5232. [Abstract] [Full Text] [PDF]
|
|